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Abstract Goniothalamin, a plant styrylpyrone derivative iso-
lated from Goniothalamus andersonii, induced apoptosis in
Jurkat T-cells as assessed by the externalisation of phosphatid-
ylserine. Immunoblotting showed processing of caspases-3 and
-7 with the appearance of their catalytically active large
subunits of 17 and 19 kDa, respectively. Activation of these
caspases was further evidenced by detection of poly(ADP-ribose)
polymerase cleavage (PARP). Pre-treatment with the caspase
inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone
(Z-VAD.FMK) blocked apoptosis and the resultant cleavage of
these caspases and PARP. Our results demonstrate that
activation of at least two effector caspases is a key feature of
goniothalamin-induced apoptosis in Jurkat T-cells.
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1. Introduction
A wealth of information is currently available on the phar-
macological activities of many natural products, in particular
their potential for use in cancer chemoprevention [1]. The
activities of these compounds include anti-proliferative, anti-
in£ammatory, anti-mutagenic and anti-oxidative mechanisms
in addition to e¡ects on drug metabolism, cell di¡erentiation
and induction of apoptosis [2]. Dysregulation of apoptosis has
now been implicated in the onset or progression of cancer [3].
Consequently, apoptosis represents an innate cellular defense
against carcinogen-induced cellular damage by removing and
inhibiting survival and growth of altered cells at di¡erent
stages of carcinogenesis [4].
Overwhelming evidence suggests the involvement of casp-
ases, a family of cysteine proteases which cleave after as-
partic acid, in mediating the biochemical events that culmi-
nate in apoptosis (reviewed in [5,6]). Currently, 14 di¡erent
caspases have been identi¢ed in humans [7,8]. Caspases exist
as inactive pro-forms and require processing to active subunits
either by autoprocessing or via activation by other caspases. It
has been proposed that ‘initiator’ caspases with long pro-do-
mains, such as caspases-8 and -9, either directly or indirectly
activate e¡ector ‘caspases’, such as caspases-3, -6 and -7 [5]. A
number of proteins have been shown to be cleaved in cells
undergoing apoptosis by the activated caspases [9]. Among
these, poly(ADP-ribose) polymerase (PARP, 113^116 kDa),
a nuclear enzyme which is activated during DNA damage, is
known to be cleaved by caspases, more speci¢cally, caspases-3
and -7. Other cellular proteins that are cleaved by caspases
include lamins, U1, 70 kDa, DNA-PK, actin and retinoblas-
toma (reviewed in [9]). Many potent selective reversible and
irreversible peptide-based inhibitors have been developed,
which have advanced our understanding of the involvement
of proteases during apoptosis [10]. Benzyloxycarbonyl-Val-
Ala-Asp £uoromethyl ketone (Z-VAD.FMK), a general casp-
ase inhibitor, has been shown to block apoptosis in many
cell types including rat hepatocytes, thymocytes and human
leukemic T-cells [11^16].
In this study, the apoptotic potential of goniothalamin, a
biologically active plant styrylpyrone derivative isolated from
Goniothalamus andersonii, was investigated in the leukemic T-
cell line Jurkat. This plant extract has recently been demon-
strated to have anti-proliferative activities in a number of
transformed cell lines including MCF-7 and HeLa cells
[17,18]. We now demonstrate for the ¢rst time that goniotha-
lamin induces apoptosis in Jurkat T-cells and that at least two
caspases, the e¡ector caspases-3 and -7, are activated as evi-
denced by cleavage of their intracellular substrate PARP.
2. Materials and methods
2.1. Jurkat T-cell culture and reagents
The leukemic T-cell line Jurkat (Clone E6-1) was obtained from
ECACC. The cells were cultured in RPMI 1640 supplemented with
10% foetal bovine serum and 1% Glutamax. Media and serum were
obtained from Life Technologies (Paisley, UK). Annexin V/FITC was
purchased from Bender Medsystems (Vienna, Austria). Z-VAD.FMK
was from Enzyme Systems (Dublin, CA, USA).
2.2. Extraction of goniothalamin
The dried powdered bark of G. andersonii (500 g) was extracted in a
Soxhlet apparatus with light petroleum ether for 72 h as described
previously [19]. Evaporation of the light petroleum ether a¡orded a
mixture of solid and thick brown oil (10 g). Column chromatography
on silica gel using light petroleum and ethylacetate mixtures as the
eluent yielded a white solid (1.5 g). Recrystallisation from light petro-
leum yielded white crystals (1 g), which were identi¢ed through spec-
troscopic data (IR, UV, MS and NMR) as goniothalamin (molecular
weight 200).
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2.3. Quanti¢cation of apoptosis by annexin V/propidium iodide staining
Apoptosis in Jurkat T-cells was induced with goniothalamin (10 Wg/
ml, equivalent to 50 WM) for 5 h. In some experiments, the cells were
pre-treated for 30 min with Z-VAD.FMK (20 WM) prior to exposure
to the apoptotic stimulus. Apoptosis was quanti¢ed by phosphatidyl-
serine (PS) exposure as described previously [20]. Brie£y, 106 cells
were centrifuged for 4 min at 200Ug and resuspended in 1 ml annexin
bu¡er. Annexin V (1.5 Wl) was added to the suspension and incubated
for 8 min at room temperature prior to addition of propidium iodide
(PI) (2.5 Wg/ml). Following a further incubation for 2 min at 4‡C, £ow
cytometric analysis was carried out using a FACScan (Becton Dick-
inson).
2.4. Western blotting
Jurkat cells (0.5U106 cells) were prepared for sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) as described pre-
viously [21]. Cellular proteins were resolved on 12% (caspases-3 and
-7) or 7% (PARP) SDS-polyacrylamide gels under denaturing condi-
tions and blotted onto a nitrocellulose membrane (Hybond-C extra,
Amersham, Bucks, UK). Pro-caspase-3 and its catalytically active
large subunit were detected with a rabbit polyclonal antibody raised
against the p17 subunit of caspase-3 (obtained from Dr D. Nicholson,
Merck Frosst, Que., Canada). Pro-caspase-7 and its catalytically large
subunit were detected with a rabbit polyclonal antibody raised against
the p19 subunit of caspase-7 [21]. Intact PARP (116 kDa) and its
85 kDa signature fragment were detected with a mouse monoclonal
antibody (C-2-10) (obtained from Dr G. Poirier, Laval University,
Que., Canada). Proteins were detected by enhanced chemilumines-
cence (Amersham).
3. Results
3.1. Goniothalamin-induced apoptosis in Jurkat cells
The e¡ects of goniothalamin, a plant extract from G. an-
dersonii, were determined in Jurkat T-cells. Cells were incu-
bated with various concentrations of goniothalamin (1^30 Wg/
ml) for 5 h. As shown in Fig. 1, this plant extract induced
apoptosis as assessed by annexin V staining in a concentra-
tion-dependent manner. The morphology of the annexin V-
labelled cells was con¢rmed as apoptotic by examination us-
ing £uorescence microscopy (data not shown). However, at
the highest concentration of goniothalamin (30 Wg/ml), the
percentage of apoptotic cells was reduced to 26.7% concom-
itant with an increase in cells including PI (51%). This is in
contrast to lower concentrations of goniothalamin where the
percentage of cells including PI was signi¢cantly lower (Fig. 1).
When analysed by £uorescence microscopy, the PI including
cells comprised ‘secondary necrotic’ or late apoptotic cells
(data not shown). Based on these observations, we concluded
that the optimal concentration of goniothalamin which in-
duced maximum apoptosis, with minimal necrosis, was
10 Wg/ml (53.45%) and this concentration was therefore used
in our future studies.
3.2. Z-VAD.FMK blocked goniothalamin-induced apoptosis
In order to understand the role of caspases in gonio-
thalamin-induced apoptosis, we pre-treated cells with Z-
VAD.FMK, a general broad-spectrum caspase inhibitor, prior
to goniothalamin exposure. This peptide-based covalent inhib-
itor has been shown to inhibit apoptosis in many mammalian
cell systems including Jurkat cells [5,15]. Apoptosis induced by
goniothalamin was inhibited back to control levels by pre-
treatment of cells with Z-VAD.FMK (20 WM) (Fig. 2). The
cytogram in Fig. 3 shows a bivariate PI/annexin V analysis of
the Jurkat cells. Viable cells were negative for both PI and
annexin V as shown in the lower left quadrant, apoptotic cells
were annexin V positive and PI negative as shown on the
upper left quadrant, while non-viable cells were positive for
both PI and annexin V (upper right quadrant). After a 5 h
exposure to goniothalamin (10 Wg/ml), the number of apop-
totic cells increased from 6.7% in the control culture to 54.5%.
Interestingly, the percentage of non-viable cells remained sim-
ilar to that in control cells con¢rming that at this concentra-
tion, goniothalamin speci¢cally induced apoptosis. Pre-treat-
ment by Z-VAD.FMK completely abrogated apoptosis in
Jurkat cells with the cytogram pro¢le being similar to that
observed in control cells (Fig. 3).
3.3. Caspases were activated in goniothalamin-induced
apoptosis
The involvement of caspases-3 and -7 in goniothalamin-
treated Jurkat cells was investigated by immunoblotting. As
shown in Fig. 4A, caspase-3 antibody detected the 32 kDa
pro-form of caspase-3 in control Jurkat cells (lane 1). In go-
niothalamin-treated cells, 45^55% of the cells were apoptotic
and a marked decrease in the levels of intact caspase-3 was
observed (lane 2). This was accompanied by the appearance of
a band corresponding to 17 kDa that represents the larger
subunit of the catalytically active caspase-3 enzyme [22]. The
loss of intact caspase-3 was reversed in cells pre-treated with
20 WM Z-VAD.FMK (lane 3). However, an additional inter-
Fig. 1. Concentration-dependent induction of apoptosis by gonio-
thalamin in Jurkat T-cells. Cells (106 cells/ml) were incubated either
alone (CON) or in the presence of various concentrations of gonio-
thalamin (GTN) for 5 h. The percentage of cell death was deter-
mined by the annexin V-FITC/PI method. Apoptosis refers to cells
which showed high annexin and low PI while non-viable refers to
cells with both high annexin and high PI staining. The data repre-
sent the means ( þ S.E.M.) of at least three separate experiments.
Fig. 2. Inhibition of goniothalamin-induced apoptosis by Z-
VAD.FMK. Cells were pre-incubated for 30 min with 20 WM Z-
VAD.FMK (ZVAD) before adding 10 Wg/ml goniothalamin (GTN)
and the % of apoptotic cells was determined by the annexin V as-
say. The data represent the means ( þ S.E.M.) of at least three sepa-
rate experiments.
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mediate band of V20 kDa appeared in these cells. This 20
kDa band was also previously observed when etoposide-medi-
ated cleavage of caspase-3 was inhibited by Z-VAD.FMK in
Jurkat T-cells [23].
In control Jurkat cells, caspase-7 was detected as a 35 kDa
protein (Fig. 4B, lane 1). After goniothalamin treatment, this
35 kDa band was reduced in intensity and was accompanied
by the appearance of a 19 kDa fragment (lane 2). The 19 kDa
band corresponds to the larger subunit of the catalytically
active caspase-7 enzyme [24]. Pre-treatment of the cells with
Z-VAD.FMK completely inhibited processing of caspase-7 to
its active subunit (lane 3). Pre-treatment of cells with Z-
VAD.FMK alone did not have any e¡ect on the levels of
either caspase-3 or -7 (Fig. 4A and B, lane 4).
The goniothalamin-induced processing of caspases-3 and -7
would indicate that these enzymes were activated in Jurkat
cells exposed to this agent. We therefore investigated whether
PARP, a preferred substrate for both caspases-3 and -7, was
cleaved in goniothalamin-treated Jurkat cells. Control cells
contained intact PARP protein of 116 kDa (Fig. 4C, lane
1). Following exposure to goniothalamin for 5 h, PARP was
cleaved extensively to its 85 kDa cleavage product (lane 2).
Pre-treatment of cells with Z-VAD.FMK completely abro-
gated cleavage of PARP in goniothalamin-treated cells (lane
3). Thus, PARP cleavage, which is indicative of a caspase-3/
-7-like proteolytic activity, was both activated and inhibited in
parallel with the processing/inhibition of these e¡ector casp-
ases.
4. Discussion
The continuing magnitude and severity of the cancer prob-
lem makes it imperative that a preventive approach to this
disease is developed. As advances in the molecular and cellu-
lar biology of carcinogenesis continue, speci¢c targets for pre-
ventive intervention are being identi¢ed and e¡ective new che-
mopreventive agents are being discovered, synthesised and
tested. In this regard, modulation of the apoptotic response
represents a novel mechanism-based approach in the identi¢-
cation or development of new therapeutic regimens for the
treatment of cancer [25,26].
In this study, we have investigated the potential role and
mechanisms of goniothalamin-induced apoptosis in the leuke-
mia T-cell line Jurkat. Goniothalamin is a natural plant ex-
tract isolated from a widely found local Malaysian plant
called G. andersonii. Although goniothalamin has been shown
Fig. 3. Flow cytometric pro¢le of Z-VAD.FMK inhibition of goniothalamin-induced apoptosis. Cells treated as in Fig. 2 were analysed for PS
exposure by measuring annexin V binding by £ow cytometry. The x-axis (FL-2 height) represents the PI staining while the y-axis (FL-1 height)
represents the annexin V labelling. The cytogram represents data typical of three separate experiments.
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to cause growth arrest, the potential apoptogenic properties of
goniothalamin have not previously been demonstrated [17,18].
When Jurkat cells were treated with increasing concentrations
of goniothalamin for 5 h, £ow cytometric analysis of PS ex-
posure revealed a concentration-dependent increase in apop-
tosis (Fig. 1). Morphological analysis by £uorescence mi-
croscopy (data not shown) con¢rmed that the cells were
apoptotic and further veri¢ed the assessment of apoptosis
by quantitation of PS exposure. At lower concentrations of
goniothalamin, i.e. below 20 Wg/ml, the morphological e¡ects
observed were mainly apoptotic with only a small percentage
of cells exhibiting either late apoptotic or ‘secondary necrotic’
e¡ects. These results demonstrate that goniothalamin is a po-
tent apoptotic inducer in Jurkat T-cells.
This is in contrast to a previous study where goniothalamin
was shown to cause primarily necrotic cell death in MCF-7
breast carcinoma cells [17]. However, it should be noted that
although maximal cytotoxicity for this cell type was observed
36 h after treatment with goniothalamin, morphological anal-
ysis was carried out at 60 h. Therefore, the possibility of
secondary necrosis occurring in these cells cannot be ruled
out.
Caspases, especially members of the caspase-3 subfamily,
are crucial mediators of apoptosis in many mammalian cells
and previous studies have demonstrated that peptide-based
caspase inhibitors, such as Z-VAD.FMK, are capable of ab-
rogating apoptosis induced by di¡erent agents in a variety of
systems [6,13,16,27^29]. To further characterise the role of
caspases in our system, we have examined the e¡ects of Z-
VAD.FMK, a general caspase inhibitor, on apoptosis induced
by goniothalamin. Pre-treatment of cells with Z-VAD.FMK
completely blocked apoptosis as assessed by the externalisa-
tion of PS. This suggests that the apoptotic signalling events
in goniothalamin-treated cells are extremely sensitive to Z-
VAD.FMK. We further con¢rmed that the e¡ector cas-
pases-3 and -7 were cleaved in goniothalamin-treated cells,
suggesting a role for caspase activation during the execution
of apoptosis. In addition, Z-VAD.FMK blocked the cleavage
of caspases-3 and -7 to their active subunits (p17 and p19,
respectively). Interestingly, the inhibition of caspase-3 process-
ing by Z-VAD.FMK produced a band migrating at approx-
imately 20 kDa. It has been shown previously that processing
of caspase-3 occurs via the generation of a p20 intermediate
that is subsequently processed to a p17 fragment [30]. Binding
of the tri-peptide inhibitor Z-VAD.FMK to the p20 subunit
of caspase-3 has also been shown to attenuate its proteolytic
activity [31].
Further evidence supporting the role of caspases-3 and -7 in
goniothalamin-induced apoptosis was obtained from the im-
munoblotting of PARP (Fig. 4C). PARP, a nuclear DNA
repair enzyme, has been shown to undergo proteolytic cleav-
age to its signature 85 kDa product during apoptosis in many
cell types and has therefore been proposed as a biochemical
marker of apoptosis [32,33]. Although most of the caspases
are capable of cleaving PARP in vitro, caspases-3 and -7 are
believed to be primarily responsible for cleavage of this pro-
tein in intact cells [5]. In this study, intact PARP was com-
pletely degraded to its 85 kDa signature fragment in gonio-
thalamin-treated cells. In this respect, Jurkat T-cells were
extremely sensitive to this treatment and almost no intact
PARP was observed in treated cells. However, goniothala-
min-induced PARP cleavage in Jurkat cells was completely
abrogated by Z-VAD.FMK. These data indicate that preven-
tion of caspase-3 and -7 activation by Z-VAD.FMK leads to
inhibition of PARP cleavage and therefore survival of these
cells.
To our knowledge, this is the ¢rst report which demon-
strates the pharmacological chemopreventive activity of go-
niothalamin in inducing apoptosis in human tumour cell lines.
Although the mechanisms by which goniothalamin impinges
on the cell death signal are currently unknown, one cannot
rule out the potential involvement of reactive oxygen inter-
mediates, genotoxic damage or upregulation of Fas ligand in
this model [34^36]. Further studies will also be required to
determine if goniothalamin can selectively induce apoptosis
in cancerous cells while leaving normal cells unharmed. In
this respect, a recent study has shown that goniothalamin
reduces rat mammary tumours induced by 7,12-dimethyl ben-
zanthracene [18]. It will therefore be important to determine
whether the tumour regression observed is a result of in-
creased apoptosis.
In conclusion, we have demonstrated that goniothalamin is
a potent apoptosis inducer in Jurkat T-cells. Induction of
apoptosis results in the activation of the e¡ectors caspases-3
and -7 during execution of the death program. The speci¢c
Fig. 4. Goniothalamin-induced processing of caspases and PARP in
Jurkat cells. Cells were treated as in Fig. 2 and immunoblotted for
(A) caspase-3, (B) caspase-7 and (C) PARP. The intact proteins are
32, 35 and 116 kDa, respectively.
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mechanism(s) by which goniothalamin initiates the apoptosis
signalling pathway is currently being investigated.
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